Compare Natera Inc. Common Stock (NTRA) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Trip.com Group Ltd — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Trip.com Group Ltd trades at $39.09 (market cap $24.60B). The key difference: Natera Inc. Common Stock is far larger — about 2.3× Trip.com Group Ltd's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Trip.com Group Ltd for 80 Days on average.
| NTRA | TCOM | |
|---|---|---|
Market Cap | $57.03B | $24.60B |
Volume | 1,131,157 | 1,981,955 |
Sector | Health | Consumer Cyclical |
52-Week High | $425.64 | $78.96 |
52-Week Low | $179.42 | $37.96 |
Typical Hold Time | 0 Days | 80 Days |
Enterprise Value | $56.18B | $16.75B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Trip.com (TCOM) trades at $38.75, down slightly by 0.03% with a bearish technical signal. The company shows strong fundamentals with impressive revenue growth from $20.0B in 2022 to $62.4B in 2025 and robust net income margins of 36.9%. Recent Q2 2026 earnings beat expectations at $1.07 per share versus $0.98 expected. Valuation metrics appear attractive with P/E of 7.48 and P/B of 1.03, while analyst consensus remains bullish with 70% buy ratings and $56.64 price target.
The stock presents a compelling value opportunity given its strong profitability and growth trajectory, though regulatory headwinds from recent antitrust penalties and competitive pressures pose risks. Technical indicators suggest near-term consolidation around $38-39 support levels, but fundamental strength supports long-term upside potential toward analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
